Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies

Fig. 1

Severity of A) headache impact (HIT-6)a and B) migraine-related disability (MIDAS)b at study baseline. HIT-6, 6-item Headache Impact Test; MIDAS, Migraine Disability Assessment. aHIT-6 score categories: ≤49 = little or no impact; 50–55 = some impact; 56–59 = substantial impact; 60–78 = severe impact. bMIDAS score grades: 0–5 = minimal or infrequent disability; 6–10 = mild or infrequent disability; 11–20 = moderate disability; ≥21 = severe disability

Back to article page